{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:57Z","timestamp":1791216537415,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AMED Practical Research Project for Rare \/ Intractable Diseases","award":["JP25ek0109824"],"award-info":[{"award-number":["JP25ek0109824"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP256f0137011"],"award-info":[{"award-number":["JP256f0137011"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Education, Culture, Sports, Science and Technology > Japan Society for the Promotion of Science","award":["23K27488"],"award-info":[{"award-number":["23K27488"]}]},{"DOI":"10.13039\/100019084","name":"Kobe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019084","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00415-026-13791-4","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:59:39Z","timestamp":1775145579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Soluble TIM-3 and galectin-9 serve as additional diagnostic biomarkers in primary central nervous system lymphoma"],"prefix":"10.1007","volume":"273","author":[{"given":"Shota","family":"Nishii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsu","family":"Akatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoka","family":"Shiroma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asato","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitaka","family":"Katanazaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Koto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sasayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4499-0790","authenticated-orcid":false,"given":"Norio","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"13791_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241259010","author":"J Wu","year":"2024","unstructured":"Wu J, Zhou D, Zhu X, Zhang Y, Xiao Y (2024) Updates of primary central nervous system lymphoma. Ther Adv Hematol. https:\/\/doi.org\/10.1177\/20406207241259010","journal-title":"Ther Adv Hematol"},{"key":"13791_CR2","doi-asserted-by":"publisher","DOI":"10.25259\/SNI_824_2020","author":"MA Kesserwan","year":"2021","unstructured":"Kesserwan MA, Shakil H, Lannon M, McGinn R, Banfield L, Nath S, Alotaibi M, Kasper E, Sharma S (2021) Frame-based versus frameless stereotactic brain biopsies: a systematic review and meta-analysis. Surg Neurol Int. https:\/\/doi.org\/10.25259\/SNI_824_2020","journal-title":"Surg Neurol Int"},{"key":"13791_CR3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-476333","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, Kaplan LD, Treseler PA, Cha S, Hwang JH, Cinque P, Cyster JG, Lowell C (2013) CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. https:\/\/doi.org\/10.1182\/blood-2013-01-476333","journal-title":"Blood"},{"key":"13791_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/srep38671","author":"Y Song","year":"2016","unstructured":"Song Y, Zhang W, Zhang L, Wu W, Zhang Y, Han X, Yang C, Zhang L, Zhou D (2016) Cerebrospinal fluid IL-10 and IL-10\/IL-6 as accurate diagnostic biomarkers for primary central nervous system large B-cell lymphoma. Sci Rep. https:\/\/doi.org\/10.1038\/srep38671","journal-title":"Sci Rep"},{"key":"13791_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3048","author":"M Maeyama","year":"2020","unstructured":"Maeyama M, Sasayama T, Tanaka K, Nakamizo S, Tanaka H, Nishihara M, Fujita Y, Sekiguchi K, Kohta M, Mizukawa K, Hirose T, Itoh T, Kohmura E (2020) Multi-marker algorithms based on CXCL13, IL-10, sIL-2 receptor, and beta2-microglobulin in cerebrospinal fluid to diagnose CNS lymphoma. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.3048","journal-title":"Cancer Med"},{"key":"13791_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s10014-012-0093-1","author":"R Kitai","year":"2013","unstructured":"Kitai R, Sasaki H, Matsuda K, Tsunetoshi K, Yamauchi T, Neishi H, Matsumura K, Tsunoda A, Takeuchi H, Sato K, Kikuta K (2013) Measurement and cellular sources of the soluble interleukin-2 receptor in primary central nervous system lymphoma. Brain Tumor Pathol. https:\/\/doi.org\/10.1007\/s10014-012-0093-1","journal-title":"Brain Tumor Pathol"},{"key":"13791_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ni833","author":"S Fillatreau","year":"2002","unstructured":"Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol. https:\/\/doi.org\/10.1038\/ni833","journal-title":"Nat Immunol"},{"key":"13791_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02552-6","author":"A Geladaris","year":"2023","unstructured":"Geladaris A, Hausser-Kinzel S, Pretzsch R, Nissimov N, Lehmann-Horn K, Hausler D, Weber MS (2023) IL-10-providing B cells govern pro-inflammatory activity of macrophages and microglia in CNS autoimmunity. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-023-02552-6","journal-title":"Acta Neuropathol"},{"key":"13791_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","author":"B Serafini","year":"2004","unstructured":"Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. https:\/\/doi.org\/10.1111\/j.1750-3639.2004.tb00049.x","journal-title":"Brain Pathol"},{"key":"13791_CR10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-8-619","author":"LA Rubin","year":"1990","unstructured":"Rubin LA, Nelson DL (1990) The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Intern Med. https:\/\/doi.org\/10.7326\/0003-4819-113-8-619","journal-title":"Ann Intern Med"},{"key":"13791_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512473362","author":"E Alvarez","year":"2013","unstructured":"Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, Cross AH (2013) CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler. https:\/\/doi.org\/10.1177\/1352458512473362","journal-title":"Mult Scler"},{"key":"13791_CR12","doi-asserted-by":"publisher","DOI":"10.1159\/000494976","author":"Y Wei","year":"2018","unstructured":"Wei Y, Chang H, Li X, Wang H, Du L, Zhou H, Xu W, Ma Y, Yin L, Zhang X (2018) Cytokines and tissue damage biomarkers in first-onset neuromyelitis optica spectrum disorders: significance of Interleukin-6. NeuroImmunoModulation. https:\/\/doi.org\/10.1159\/000494976","journal-title":"NeuroImmunoModulation"},{"key":"13791_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280209","author":"SD Kittur","year":"1990","unstructured":"Kittur SD, Kittur DS, Soncrant TT, Rapoport SI, Tourtellotte WW, Nagel JE, Adler WH (1990) Soluble Interleukm-2 receptors in cerebrospinal fluid from individuals with various neurological disorders. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.410280209","journal-title":"Ann Neurol"},{"key":"13791_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3606970","author":"C Chiavazza","year":"2018","unstructured":"Chiavazza C, Pellerino A, Ferrio F, Cistaro A, Soffietti R, Ruda R (2018) Primary CNS lymphomas: challenges in diagnosis and monitoring. Biomed Res Int. https:\/\/doi.org\/10.1155\/2018\/3606970","journal-title":"Biomed Res Int"},{"key":"13791_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15410","author":"A van Westrhenen","year":"2018","unstructured":"van Westrhenen A, Smidt LCA, Seute T, Nierkens S, Stork ACJ, Minnema MC, Snijders TJ (2018) Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.15410","journal-title":"Br J Haematol"},{"key":"13791_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.010","author":"AJM Ferreri","year":"2024","unstructured":"Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, Cwynarski K, Fox CP, Hoang-Xuan K, Malaise D, Ponzoni M, Schorb E, Soussain C, Specht L, Zucca E, Buske C, Jerkeman M, Dreyling M, Eha clinicalguidelines@esmo.org EGCEa (2024) Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.010","journal-title":"Ann Oncol"},{"key":"13791_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18598","author":"CL Cheng","year":"2023","unstructured":"Cheng CL, Yao CY, Huang PH, Yu CW, Fang WQ, Chuang WH, Wu SJ, Lin YJ, Hung YC, Tsai CH, Yu SC, Chou WC, Tien HF (2023) Cerebrospinal fluid soluble Programmed Death-Ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.18598","journal-title":"Br J Haematol"},{"key":"13791_CR18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-144882","author":"RSD Severinsen","year":"2021","unstructured":"Severinsen RSD, Enemark MB, Mortensen JB, Kjeldsen E, Thorsgaard M, Pulczynski EJ, Oettingen G, M\u00f8ller HJ, Vejgaard C, Bjerre M, d\u2019Amore F (2021) Patients with Primary Central Nervous System Lymphoma have high levels of Soluble Programmed Cell Death Protein 1 in their pretherapeutic cerebrospinal fluid. Blood. https:\/\/doi.org\/10.1182\/blood-2021-144882","journal-title":"Blood"},{"key":"13791_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf208\/8257595","author":"JLM van Rooij","year":"2025","unstructured":"van Rooij JLM, Wessels PH, Delemarre EM, Meek B, Ruven HJT, Seute T, Minnema MC, Nierkens S, Snijders TJ (2025) New biomarkers for the diagnosis of primary central nervous system lymphoma in CSF: a multicenter retrospective cohort study. Neuro-Oncol Adv. https:\/\/doi.org\/10.1093\/noajnl\/vdaf208\/8257595","journal-title":"Neuro-Oncol Adv"},{"key":"13791_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG (2015) International consensus diagnostic criteria for Neuromyelitis Optica Spectrum Disorders. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"13791_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"13791_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.2295","author":"BJ Stern","year":"2018","unstructured":"Stern BJ, Royal W 3rd, Gelfand JM, Clifford DB, Tavee J, Pawate S, Berger JR, Aksamit AJ, Krumholz A, Pardo CA, Moller DR, Judson MA, Drent M, Baughman RP (2018) Definition and consensus diagnostic criteria for Neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2018.2295","journal-title":"JAMA Neurol"},{"key":"13791_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.76","author":"J Birnbaum","year":"2009","unstructured":"Birnbaum J, Hellmann DB (2009) Primary angiitis of the central nervous system. Arch Neurol. https:\/\/doi.org\/10.1001\/archneurol.2009.76","journal-title":"Arch Neurol"},{"key":"13791_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7209-3","author":"S Kalra","year":"2014","unstructured":"Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, Houman H, Mahr A, Salvarani C, Sfikakis PP, Siva A, Al-Araji A (2014) Diagnosis and management of Neuro-Behcet\u2019s disease: international consensus recommendations. J Neurol. https:\/\/doi.org\/10.1007\/s00415-013-7209-3","journal-title":"J Neurol"},{"key":"13791_CR25","doi-asserted-by":"publisher","DOI":"10.2176\/nmc.st.2020-0292","author":"M Nakajima","year":"2021","unstructured":"Nakajima M, Yamada S, Miyajima M, Ishii K, Kuriyama N, Kazui H, Kanemoto H, Suehiro T, Yoshiyama K, Kameda M, Kajimoto Y, Mase M, Murai H, Kita D, Kimura T, Samejima N, Tokuda T, Kaijima M, Akiba C, Kawamura K, Atsuchi M, Hirata Y, Matsumae M, Sasaki M, Yamashita F, Aoki S, Irie R, Miyake H, Kato T, Mori E, Ishikawa M, Date I, Arai H, Research Committee of Idiopathic Normal Pressure H (2021) Guidelines for management of idiopathic normal pressure hydrocephalus (third edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus. Neurol Med Chir (Tokyo). https:\/\/doi.org\/10.2176\/nmc.st.2020-0292","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"13791_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/bs.mie.2019.06.001","author":"JS Lehmann","year":"2019","unstructured":"Lehmann JS, Rughwani P, Kolenovic M, Ji S, Sun B (2019) LEGENDplex: bead-assisted multiplex cytokine profiling by flow cytometry. Methods Enzymol. https:\/\/doi.org\/10.1016\/bs.mie.2019.06.001","journal-title":"Methods Enzymol"},{"key":"13791_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK (2024) LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. https:\/\/doi.org\/10.1016\/j.immuni.2024.01.010","journal-title":"Immunity"},{"key":"13791_CR28","doi-asserted-by":"publisher","DOI":"10.7150\/thno.54343","author":"M Alame","year":"2021","unstructured":"Alame M, Cornillot E, Cacheux V, Rigau V, Costes-Martineau V, Lacheretz-Szablewski V, Colinge J (2021) The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling. Theranostics. https:\/\/doi.org\/10.7150\/thno.54343","journal-title":"Theranostics"},{"key":"13791_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123073","author":"HG Wirsching","year":"2021","unstructured":"Wirsching HG, Weller M, Balabanov S, Roth P (2021) Targeted therapies and immune checkpoint inhibitors in primary CNS lymphoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13123073","journal-title":"Cancers (Basel)"},{"key":"13791_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2425131","author":"Q Jin","year":"2024","unstructured":"Jin Q, Jiang H, Han Y, Zhang L, Li C, Zhang Y, Chai Y, Zeng P, Yue L, Wu C (2024) Tumor microenvironment in primary central nervous system lymphoma (PCNSL). Cancer Biol Ther. https:\/\/doi.org\/10.1080\/15384047.2024.2425131","journal-title":"Cancer Biol Ther"},{"key":"13791_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05560-4","author":"C Li","year":"2024","unstructured":"Li C, Zhang L, Jin Q, Jiang H, Wu C (2024) Role and application of chemokine CXCL13 in central nervous system lymphoma. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-023-05560-4","journal-title":"Ann Hematol"},{"key":"13791_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.393","author":"T Shichijo","year":"2022","unstructured":"Shichijo T, Tatetsu H, Nosaka K, Higuchi Y, Kikukawa Y, Inoue Y, Toyoda K, Yasunaga J, Matsuoka M (2022) Predictive impact of soluble interleukin\u20102 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B\u2010cell lymphoma. eJHaem. https:\/\/doi.org\/10.1002\/jha2.393","journal-title":"eJHaem"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13791-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13791-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13791-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T01:48:23Z","timestamp":1776649703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13791-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["13791"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13791-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NC has received honoraria for lectures from Biogen Japan, Novartis, Tanabe Pharma, Chugai Pharmaceutical, and Alexion Pharmaceuticals. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The protocol was approved by Kobe University Clinical Research Ethical Committee (B250069) in accordance with the Declaration of Helsinki. Because the research involved the use of existing clinical data, informed consent was obtained through an opt-out process. Study information was publicly available on the institutional website, providing patients with the opportunity to withdraw their data from the analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"248"}}